A remarkable, dose-dependent inhibition of tumor growth was observed in mice with admixed PBMCs treated with the CD1d-Vδ2 hu-bsTCE; tumor growth was only observed after discontinuation of bsTCE treatment (Figure 6C and S5C). The gene discussed is CD1D; the disease is neoplasm.